146 results about "Hydroxybutyrates" patented technology

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and / or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

The present embodiment relates to a biodegradable resin composition, a biodegradable film using the same, and a method for preparing the same, wherein the biodegradable resin composition comprises: a polylactic acid (PLA) resin; and a polyhydroxyalkanoate (PHA) resin. The PHA resin includes: a first PHA resin including a 3-hydroxyhexanoate (3HH) repeating unit; and a second PHA resin comprising a 4-hydroxybutyrate (4HB) repeating unit, thereby simultaneously improving the biodegradability, stretchability, and strength of the biodegradable film. Therefore, the biodegradable resin composition according to an embodiment of the present invention has excellent biodegradability and biocompatibility, and thus is environmentally friendly, and can ensure sufficient stretchability and strength thereof to produce a stretchable film, thereby being used for producing various products requiring moldability, and also being suitable for the production of various products requiring moldability. The present invention relates to a packaging material, such as a packaging material for disposable bags or food containers, and exhibits excellent properties.

The invention provides a polyhydroxyalkanoate composition as well as a preparation method and application thereof. The polyhydroxyalkanoate composition comprises at least two kinds of copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate. The at least two copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate at least comprise one segmented copolymer of 3-hydroxybutyrate and 4-hydroxybutyrate, and in the segmented copolymer, the mass percentage content of a 4-hydroxybutyrate structural unit is 0-20%; the at least two copolymers of the 3-hydroxybutyrate and the 4-hydroxybutyrate at least comprise a random copolymer of the 3-hydroxybutyrate and the 4-hydroxybutyrate. The polyhydroxyalkanoate composition has good strength and toughness, the post-brittleness is also obviously improved, and meanwhile, the polyhydroxyalkanoate composition also has good processability and migration resistance.

The invention belongs to the technical field of biological medicines, and particularly relates to application of beta-hydroxybutyrate in preparation of a medicine for preventing or treating hepatocellular carcinoma. The invention provides an application of beta-hydroxybutyrate in preparation of a medicine for preventing and / or treating hepatocellular carcinoma. The beta-hydroxybutyrate comprises a beta-hydroxybutyrate or a combination of a plurality of beta-hydroxybutyrates. A series of experimental data show that beta-hydroxybutyrate not only can effectively improve fatty degeneration and inflammatory response of hepatocytes, but also can remarkably reduce the risk of occurrence of metabolic dysfunction related hepatocellular carcinoma (HCC), and can inhibit malignant biological characteristics of HCC. The invention provides a powerful scientific basis for the development of novel HCC prevention and treatment medicines, and has a wide clinical application prospect.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

The application provides a preparation method of piezoelectric nanofiber aerogel, comprising the following steps: S1, zinc oxide is added into hexafluoroisopropanol, polyhydroxybutyrate is added after ultrasonic dispersion, and magnetic stirring is conducted to obtain a PHB@ZnO solution; S2, the PHB@ZnO solution is prepared into a nanofiber membrane through electrospinning, the nanofiber membrane is placed into a vacuum drying box for vacuum drying to obtain a PHB@ZnO nanofiber membrane; S3, the PHB@ZnO nanofiber membrane is added into deionized water, and a short PHB@ZnO nanofiber dispersion liquid is obtained after homogenization; S4, chitosan powder is added into deionized water, glacial acetic acid is added after stirring, and chitosan solution is obtained after continuous stirring; S5, the short PHB@ZnO nanofiber dispersion liquid, the chitosan solution and glutaraldehyde are uniformly mixed to obtain a mixture, the mixture is poured into a mold, the mold is placed into a freeze dryer for freeze drying to obtain piezoelectric nanofiber aerogel. The piezoelectric nanofiber aerogel prepared by the piezoelectric nanofiber aerogel has a porous structure and good piezoelectric performance, and can accelerate bone defect repair.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

A poly(3-hydroxyalkanoate) resin composition comprising: a copolymer (A) of 3-hydroxybutyrate units and other hydroxyalkanoate units, and a copolymer (B) of 3-hydroxybutyrate units and other hydroxyalkanoate units, wherein the content of other hydroxyalkanoate units in copolymer (A) is 1 to 6 mol%, and the content of other hydroxyalkanoate units in copolymer (B) is 24 mol% or more. The resin composition further comprises layered clay mineral (C). The proportion of (A) is 72 to 93 wt%, and the proportion of (B) is 7 to 28 wt%. The content of (C) is 5 to 45 parts by weight relative to 100 parts by weight of the total poly(3-hydroxyalkanoate) resin composition.

Provided is a resin tube containing a poly(3-hydroxyalkanoate)-based resin component. The resin component contains a poly(3-hydroxyalkanoate)-based resin (A) having a weight average molecular weight of 100,000 to 700,000 (exclusive of 700,000), and a copolymer (B) of a 3-hydroxybutyrate unit having a weight average molecular weight of at least 700,000 and another hydroxyalkanoate unit. The content ratio of the 3-hydroxybutyrate unit in the copolymer (B) is 76 mol% to 100 mol% (exclusive of 100 mol%). The content of the resin (A) in the total amount of the poly(3-hydroxyalkanoate)-based resin component is 80 wt% to 99 wt%, and the content of the copolymer (B) is 1 wt% to 20 wt%. The 50% fracture energy of the resin tube at 23°C is more than 0.625 J.

Provided is a fiber containing a poly (3-hydroxyalkanoate)-based resin, the fiber containing a poly (3-hydroxyalkanoate)-based resin containing a 3-hydroxybutyrate unit, the fiber being suppressed in melt adhesion during the production of the fiber and being capable of being thermally fused under low-temperature conditions during thermal processing of the fiber. The present invention is a fiber having a core-sheath structure including a core part and a sheath part, the core part and the sheath part each containing a poly (3-hydroxyalkanoate)-based resin including a 3-hydroxybutyrate unit, the average molar content of 3-hydroxybutyrate units in the poly (3-hydroxyalkanoate)-based resin in the core part is greater than the average molar content of 3-hydroxybutyrate units in the poly (3-hydroxyalkanoate)-based resin in the sheath part.

A method for catalyzing the thermal decomposition of polyβ-hydroxybutyrate using a metal catalyst. The present invention belongs to the technical field of chemical recovery of organic materials. The present invention addresses the technical problem that existing methods for thermal decomposition of discarded polyβ-hydroxybutyrate require harsh conditions and the use of toxic catalysts, and lack a green catalytic system and method that can quickly and efficiently thermally decompose polyβ-hydroxybutyrate under mild conditions. The present invention uses green and environmentally friendly metal zinc and magnesium catalysts to catalyze the thermal decomposition of polyβ-hydroxybutyrate. The catalyst is non-toxic and odorless, has little harm to the environment, and can avoid the harm to the ecological environment caused by the use of other toxic metal catalysts. At the same time, the catalytic system of the present invention has a high catalytic efficiency and can catalyze the rapid and efficient thermal decomposition of polyβ-hydroxybutyrate under mild conditions, thereby avoiding the increase in energy consumption caused by reaction conditions such as high temperature and high pressure. It is helpful to achieve green recycling of discarded polyβ-hydroxybutyrate plastics.

The invention belongs to the technical field of plastic packaging bag preparation, and particularly relates to a degradable high-toughness e-commerce plastic packaging bag material and a preparation method thereof.The degradable high-toughness e-commerce plastic packaging bag material is prepared from, by mass, 55-68% of polylactic acid-polyhydroxybutyrate copolymer (PLA-PHB) and 10-15% of linear low density polyethylene (LLDPE) through a melt blending-twin-screw extrusion technology. A reinforcement phase: 25-30% of corn straw fiber (modified by a silane coupling agent KH-550), 5-8% of kudzu stem and leaf fiber, and 3-5% of cotton and linen fiber; through synergistic enhancement of the PLA-PHB copolymer (60%) and the modified corn straw fiber (28%), the tensile strength of the material reaches 42 MPa (60% higher than that of pure PLA), the elongation at break breaks through 520% (generally, the natural composting degradation rate in 90 days reaches 35%, the balance of'high strength and high toughness' and'rapid degradation 'is achieved for the first time, and the application prospect is broad. And the composite requirements of e-commerce packaging for impact resistance, tear resistance and end processing efficiency are met.

The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

Provided is an implant comprising a first biodegradable polymer and a second biodegradable polymer wherein the first biodegradable polymer comprises a copolymerized polyhydroxyalkanoate (PHA) and the copolymerized PHA comprises from 0.1 to 50 wt%, based on the total weight of the copolymerized PHA, of recurring units derived from 4-hydroxybutyrate (4-HB).

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

The application provides an ADR chain extender modified poly(-3-hydroxybutyrate-co-3-hydroxyhexanoate) and a preparation method and application thereof. The full-biological antibacterial film can be prepared by blending the ADR chain extender modified poly(-3-hydroxybutyrate-co-3-hydroxyhexanoate) polymer and the epoxy soybean oil modified starch. The epoxy soybean oil modified starch has a core-shell structure, the existence of the shell can prevent the starch from absorbing water, improve the water resistance of the full-biological antibacterial film, and prolong the shelf life. Meanwhile, after the poly(-3-hydroxybutyrate-co-3-hydroxyhexanoate) polymer is modified by the ADR chain extender, the molecular weight can be significantly increased, so that the tear resistance and tensile strength of the full-biological antibacterial film can be obviously improved, and the full-biological antibacterial film also has excellent antibacterial performance.

A process for producing polyhydroxyalkanoates, comprising the steps of: fermenting production medium comprising pongamia oil using bacteria from the Cupriavidus, Burkholderia, or Alcaligenes genera capable of producing polyhydroxyalkanoates; wherein the pongamia oil is extracted from the seeds of Pongamia species and clarified by filtering before the crude, unprocessed pongamia oil is added to the production medium; and extracting the polyhydroxyalkanoates comprising a homopolymer comprising a 3-hydroxybutyrate (3HB) unit amongst other sole PHB polymers from within the bacteria.

A resin composition for injection molding contains a poly(3-hydroxyalkanoate) resin. The poly(3-hydroxyalkanoate) resin includes at least one copolymer of 3-hydroxybutyrate units and other hydroxyalkanoate units. The average content of the 3-hydroxybutyrate units in the poly(3-hydroxyalkanoate) resin is from 92 to 99 mol %. The polystyrene-equivalent weight-average molecular weight of the poly(3-hydroxyalkanoate) resin, as measured by gel permeation chromatography using a chloroform solvent, is from 21×104 to 38×104. In a weight molecular weight distribution of the poly(3-hydroxyalkanoate) resin, the proportion of a component having a weight molecular weight of 20×104 or less is from 35 to 60 wt %.

To provide a biomass-derived plasticizer for polyester resins with excellent plasticization efficiency. [Solution] A plasticizer containing 3-hydroxybutyrate ester is prepared as a plasticizer for plasticizing polyester resins. The 3-hydroxybutyrate ester may also contain R-3-hydroxybutyrate ester. The 3-hydroxybutyrate ester may also contain 3-hydroxybutyrate alkyl ester. The 3-hydroxybutyrate alkyl ester may contain 3-hydroxybutyrate C 1-24 Alkyl esters (especially 3-hydroxybutyrate C) 1-6 It may also contain alkyl esters. A polyester resin composition comprising a polyester resin and the plasticizer may be prepared. The polyester resin may include a biodegradable polyester resin such as polylactic acid. The mass ratio of the polyester resin to the plasticizer may be 99 / 1 to 80 / 20. A molded article containing the polyester resin composition may be prepared.

The invention provides a polyhydroxyalkanoate composition, a preparation method of the polyhydroxyalkanoate composition, a biodegradable plastic product and application of the biodegradable plastic product. The biodegradable plastic product is prepared by the following method which comprises the following steps: mixing at least two copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate, melting, extruding and granulating to obtain polyhydroxyalkanoate particles; the at least two copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate at least comprise a block copolymer of which the mass percentage content of a 4-hydroxybutyrate structural unit is 0-20%, and at least comprise a random copolymer of 3-hydroxybutyrate and 4-hydroxybutyrate; forming the polyhydroxyalkanoate particles to obtain a preformed part; and carrying out post-treatment on the preformed part to obtain the biodegradable plastic product. The biodegradable plastic product has the advantages of excellent toughness, low migration volume, good processing molding performance and low odor.

An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.

Provided are: a fabric that has strength sufficient for practical use as clothing or industrial materials and also has excellent color fastness while containing PHA fibers having marine biodegradability; and a dyeing method for obtaining said fabric. The present invention pertains to a dyed fabric which includes polyhydroxyalkanoate fibers including 3-hydroxybutyrate as a monomer unit and having a degree of crystallinity of 50% or more and which exhibits a K / S value of 2 or more. The present invention also pertains to a dyeing method for a fabric which includes polyhydroxyalkanoate fibers including 3-hydroxybutyrate as a monomer unit and having a degree of crystallinity of 50% or more. In the dyeing method, the temperature of a dyeing solution during dyeing is 86-120°C.

The objective of the present invention is to provide a novel production method allowing a molded body containing a P3HB-based resin to be obtained using an injection blow molding method, and a technique for using the same. The above problem is solved by providing a method for producing a molded body containing a P3HB-based resin, the method comprising the steps (A) to (C): (A) the step of plasticizing a resin composition containing a P3HB-based resin; (B) the step of injection molding the plasticized resin composition obtained in the previous step (A), to obtain a preform; and (C) the step of blow-forming the preform obtained in the previous step (B), to obtain a molded body.

Provided is a resin film containing a reaction product of 100 parts by weight of a poly(3-hydroxyalkanoate) resin component and 0.01 to 0.5 parts by weight of an organic peroxide. The poly(3-hydroxyalkanoate) resin component includes: a copolymer (A) which is a copolymer of 3-hydroxybutyrate units and 3-hydroxyhexanoate units and in which a content of the 3-hydroxyhexanoate units is from 1 to 6 mol %; and a copolymer (B) which is a copolymer of 3-hydroxybutyrate units and 3-hydroxyhexanoate units and in which a content of the 3-hydroxyhexanoate units is 24 mol % or more.

A resin composition contains: a copolymer (A) that is a copolymer of 3-hydroxybutyrate units and other hydroxyalkanoate units and in which the proportion of the other hydroxyalkanoate units is 24 mol % or more; a copolymer (B) that is a copolymer of 3-hydroxybutyrate units and other hydroxyalkanoate units and in which the proportion of the other hydroxyalkanoate units is from 1 to less than 5 mol %; and a copolymer (C) that is a copolymer of 3-hydroxybutyrate units and other hydroxyalkanoate units and in which the proportion of the other hydroxyalkanoate units is from 5 to less than 24 mol %. The copolymer (A) has a weight-average molecular weight of 10×104 to 50×104. At least one or all of the copolymers (A), (B), and (C) are reaction products resulting from a reaction with an organic peroxide.

The present invention provides pharmaceutical compositions and methods for treating fatigue or excessive daytime sleepiness associated with narcolepsy. [Solution] A pharmaceutical composition comprising an immediate-release component containing 4-((L-valyl)oxy)butanoic acid and a controlled-release component containing 4-((L-valyl)oxy)butanoic acid, as well as the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and γ-hydroxybutyrate after oral administration of the pharmaceutical composition are disclosed.

The application relates to the technical field of slow-release hydrogels, and discloses a periodontal local drug slow-release hydrogel based on chitosan and application thereof, which is prepared from the following components: triple modified chitosan, functional filler, therapeutic drug, crosslinking agent and deionized water; the triple modified chitosan is carboxymethylization-mussel biomimetic polyphenol-poly-beta-hydroxybutyrate triple modified chitosan, and the functional filler is a composite powder of hydroxyapatite and carboxylated graphene oxide loaded with nano-silver; the technical scheme of the application solves the technical problems of poor water solubility, insufficient wet adhesion, short slow-release period and single function of the existing chitosan hydrogel, the prepared hydrogel is suitable for the physiological environment of periodontal local, has excellent biocompatibility, structural stability, long-acting slow-release property and multifunctional synergy, provides a brand-new effective carrier for long-acting local treatment of periodontitis, and has extremely high practical value and popularization prospect in the field of oral clinical treatment.

The present invention relates to a nutritional composition comprising 3-hydroxybutyric acid for use in improving the gastrointestinal barrier. In particular, the present invention relates to improving the gastrointestinal barrier in an individual, preferably an infant or a child.

The present disclosure relates to highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate and biomedical uses thereof. In particular highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate, is provided for enhancing bodily function and treating various disease states. The methods described herein provide for production of a highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate via processes external to the human body and administering effective amounts of highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate to human subjects to achieve a range of therapeutic benefits, including but not limited to, one or more of: inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, and promoting muscle protein synthesis. Additionally, highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate is administered in an amount and frequency conducive to one or more of: improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection. Methods for manufacturing and purifying (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate compositions to ensure high specificity and efficacy in therapeutic applications are also provided.